CLDF Title
Home | Contact Us | Bookmark
MASH HCC ALCOHOL LIVER DISEASE PEDIATRIC LIVER DISEASE
Embassy of Education
Webcasts Abstract Library LiverQ Academy National Conference Regional Conferences
 
Back  
 
Reuters Health Information (2009-10-16): Second test backs single dose of Glaxo H1N1 shot

Clinical

Second test backs single dose of Glaxo H1N1 shot

Last Updated: 2009-10-16 16:00:54 -0400 (Reuters Health)

* Second study shows one Pandemrix dose gives good response

* Glaxo stepping up shipments of vaccine to governments

LONDON (Reuters) - GlaxoSmithKline said on Friday a second clinical trial of its adjuvanted H1N1 swine flu vaccine Pandemrix had confirmed that a single dose could provide a strong immune response.

Glaxo's vaccine -- containing an additive, or adjuvant, to boost its effectiveness -- was approved for use in Europe last month. It has not been cleared for use in the United States.

Experts had initially expected adults would need two doses of H1N1 vaccine to get a good response. But clinical trials with shots from companies including Glaxo, Sanofi-Aventis, Novartis and CSL now suggest one dose is probably enough.

The British-based drugmaker recently started sending supplies of Pandemrix to governments and said it had delivered more than 7 million doses in the first week of shipments, adding that deliveries would increase in the coming weeks.

Britain is one of the first countries to receive the vaccine. Officials said on Thursday that millions of doses of the Glaxo vaccine would be available for use throughout the state health service by the end of this month.

 
 
 
 

Subscribe

Be the first to know about our latest upcoming programs and events!

CLDF

Follow us

The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2025 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.